TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Probability of producing a response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Level of ACTH in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Level of CORT in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Lymphocyte proliferative reaction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: TMAO production capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: intestinal microbiota composition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: vascular inflammation parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: VISA scores improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: vWF levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Mid-septal T2* value
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nonresponse to escitalopram treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in extrinsic stain formation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FCD (Flow Cytometry Data)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Age at first sex
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Condom use at first sex
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Use of contraception at first sex
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Grade III-IV leukopenia
Endpoint domain: Adverse events/effects
Primary endpoint: Grade III-IV thrombocytopenia
Endpoint domain: Adverse events/effects
Primary endpoint: Grade III-IV anemia
Endpoint domain: Adverse events/effects
Primary endpoint: Ultrastructural changes in antral mucosa
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Reduction of PPH near misses
Endpoint domain: Mortality/survival
Primary endpoint: Decrease in long-term PPH near miss case fatality
Endpoint domain: Mortality/survival
Primary endpoint: Proportion of PPH cases treated with intravenous oxytocin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: TMD symptoms' relief
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MMP‐2 activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in mean total daily dose of cyclosporine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Discounted itraconazole daily drug cost
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: CHEOPS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: well being
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: self-rated symptom relief
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: duration of full recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: duration in the postanesthesia care unit
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean differences in compound action potential (CAP) amplitudes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: III/V and I/V amplitude ratios
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: BTT (Brainstem Transmission Time) changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Accurate measurements of the working length of root canals
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NDLQI score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: NDSI score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean grey levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Coefficient of variation (CV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence rate of clinical malaria episodes
Endpoint domain: Adverse events/effects
Primary endpoint: SCORing of Atopic Dermatitis (SCORAD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Children's Dermatology Life Quality Index
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Bacterial skin colonization with S. aureus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: coronary death or nonfatal myocardial infarction
Endpoint domain: Mortality/survival
Primary endpoint: Serum TG concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Magnitude of postprandial lipemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: change in general intelligence factor score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Postoperative abnormal thresholds for Semmes-Weinstein monofilaments
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Two-point discrimination on lower lip and chin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Self-reported changes in lower lip sensation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Prevention of NSAID-induced gut injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Mean Lanza scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Risk of developing >2 erosions or an ulcer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Eradication of infections
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Amelioration of CSS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of postdural puncture headache (PDPH)
Endpoint domain: Adverse events/effects
Primary endpoint: hospitalization rates from the emergency department
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: symptom persistence at 10 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pre-operative anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: maximal voluntary muscle power
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ischemic outcomes (cardiovascular death, myocardial infarction or stroke)
Endpoint domain: Mortality/survival
Primary endpoint: Bleeding outcomes
Endpoint domain: Adverse events/effects
Primary endpoint: Undetectable HBV DNA at week 52
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean HBV DNA reduction from baseline to week 52
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 10-year graft survival rates
Endpoint domain: Mortality/survival
Primary endpoint: rate of complete functional recovery after AR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnosis of Acute Coronary Syndrome (ACS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Expression level of KL-6
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acceptability of SILCS gel delivery system
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Pelvic floor symptom bother
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in tinnitus severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: axial hardness values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean one-month planning behavior score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Overall pain reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC(0-12h) of mycophenolic acid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Percentage of subjects with a ≥ 50% reduction from baseline in sperm concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: C. glabrata colonization
Endpoint domain: Infections and infestations outcomes
Primary endpoint: IC due to C. glabrata
Endpoint domain: Infections and infestations outcomes
Primary endpoint: Acquired IC in the ICU
Endpoint domain: Infections and infestations outcomes
Primary endpoint: favorable outcome (modified Rankin Scale 0 to 2) at 90 days
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Reduction in sitting diastolic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Spinal Cord Injury (SCI) incidence
Endpoint domain: Adverse events/effects
Primary endpoint: Periodontal health (PI and PD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HRS reversal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Survival for 90 days without a transplant
Endpoint domain: Mortality/survival
Primary endpoint: 6MWT walk distance after EECP therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: self-assessed VAS scores
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: visual analog pain score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Beck's Depression Inventory (BDI) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Surgical interventions
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: YMRS total score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HAMD-21 total score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient-centered nature of sessions
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Verbal activity of visit companions
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Disclosure of medical information by visit companions
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: MMAS score improvement
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Incidence rates of cholera
Endpoint domain: Adverse events/effects
Primary endpoint: Patient rating of study medication as very good or excellent
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Duration of activity of SR paracetamol compared to IR paracetamol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progression of stenoses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: prevalence of risky drinking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Need for aortic surgery, aortic dissection, or death
Endpoint domain: Mortality/survival
Primary endpoint: Aortic dilation rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes in rSO2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean cumulative pain score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: total amounts of opioid consumed
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Effect on relapses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effect on MRI activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients with observed shivering
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: overall recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: proximal recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: advanced adenoma recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Sensitivity of MR imaging for detecting mandibular invasion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Positive predictive value of MR imaging
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Withdrawal symptoms assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Avoidance of unnecessary biopsies
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Improvement in somatic complaints
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in hopefulness
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Grades 3-5 pneumonitis
Endpoint domain: Adverse events/effects
Primary endpoint: DRE rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sleep Efficiency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Polysomnographic parameters of sleep initiation and maintenance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Goal setting from pain oriented towards function restore and RTW
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Perceived applicability and effectiveness of the programme
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Gastric mucosal image quality
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma antioxidant capabilities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: XOX activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: APTT prolongation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: INR increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: incidence of early posttransplant diabetes mellitus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: average dosage of insulin consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: incidence of infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: length of stay in ICU
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: average hospital expenses
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: gastrointestinal dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: severe neurologic sequelae
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: incremental cost-effectiveness per life-year saved
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Pharmacokinetic exposure of O-desmethyltramadol and celecoxib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Parkinsonian motor symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Quantified Denver Scale of Communicative Function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mental Component Score of the Short‐Form 36
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Hearing Handicap Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: in-stent neointimal volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: overall cost of care
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Efficacy in hypotension prophylaxis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean interruption of the operative procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of DEs requiring substantial therapeutic intervention
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of DE treatment days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to first DE requiring intervention
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Latent time of EP in visual field
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Amplitude of EP in upper visual field
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Amplitude of EP in lower visual field
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: decrease in arterial wave reflections
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: decrease in carotid SBP and pulse pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: decrease in aortic pulse wave velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Volume of drainage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative visual analogue scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Receipt of shorter course ADT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neurological status of full recovery or mild impairment at discharge
Endpoint domain: Mortality/survival
Primary endpoint: Mean time to complete sensory block
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in total cholesterol levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reduction in triglycerides levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Tolerance of TMS cortical stimuli
Endpoint domain: Adverse events/effects
Primary endpoint: prevalence of complications
Endpoint domain: Adverse events/effects
Primary endpoint: Relative blood flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Right ventricular to systemic systolic blood pressure ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Improved steatosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Normalized transaminase levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: aggregated STI prevalence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: hazard of CTF per unit increase of inflammation factor score
Endpoint domain: Mortality/survival
Primary endpoint: High well-being (score ≥ 6)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: COPD admissions or death
Endpoint domain: Mortality/survival
Primary endpoint: Intraperitoneal glucose load
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Ultrafiltration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: clinical main symptom disappearance rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Crohn's Disease Activity Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inflammatory bowel disease questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Serum C-reactive protein concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of nausea and/or vomiting
Endpoint domain: Adverse events/effects
Primary endpoint: postoperative hemoglobin (hb) and hematocrit (htc) values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: luminescence ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Whole-blood international normalized ratios (INRs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: DX-9065a plasma levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anti-FXa levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: uSBS (Universal Shear Bond Strength)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: insertion-related pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: injection-related pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fasting blood glucose (FBG) level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Postprandial blood glucose (PBG) level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Reduction of systolic blood pressure (SBP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage reduction of left ventricular mass index (LVMI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes